Two‐decade battle with myasthenia gravis: A breakthrough case report on the long‐term success with eculizumab and ravulizumab treatment

Abstract

Key Clinical Message This unique case of generalized myasthenia gravis shows sustained stability of a patient's condition for 3 years with eculizumab/ravulizumab treatment following 16 years of refractory disease. It highlights the long‐term effectiveness of C5 inhibitors in a real‐world setting, aiding physicians in their decision‐making for refractory cases and treatment discontinuation scenarios.

Keywords

• eculizumab
• generalized myasthenia gravis
• myasthenia gravis
• ravulizumab